MINI FUTURE LONG - ZEALAND PHARMA | Real-time Bid/Ask 03:11:12 2024-06-06 EDT | ||
| 3.9 EUR / 3.95 EUR | +1.16% |
|
| 1 month | -3.48% | ||
| 3 months | -26.10% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ZEALAND PHARMA A/S
Latest news about ZEALAND PHARMA A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-05 | 3.88 | -0.26% |
| 24-06-04 | 3.89 | -10.78% |
| 24-06-03 | 4.36 | +2.35% |
| 24-05-31 | 4.26 | +12.40% |
| 24-05-30 | 3.79 | -2.32% |
Delayed Quote Börse Stuttgart
Last update June 05, 2024 at 02:42 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ZEALAND PHARMA A/S |
| Issuer | Morgan Stanley |
| WKN | ME6R7A |
| ISIN | DE000ME6R7A1 |
| Date issued | 2024-01-10 |
| Strike | 320.5 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.17 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.01 € |
|---|---|
| Lowest since issue | 1.35 € |
| Spread | 0.05 € |
| Spread % | 1.24% |
Company Profile
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
-
Consensus: Zealand Pharma A/S
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
610.5
DKK
Average target price
785.6
DKK
Spread / Average Target
+28.68%
- Stock Market
- Certificates
- Certificat
